TUCSON, Ariz. (AP) _ Accelerate Diagnostics Inc. (AXDX) on Thursday reported a loss of $20.8 million in its second quarter.
On a per-share basis, the Tucson, Arizona-based company said it had a loss of 38 cents.
The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 40 cents per share.
The maker of systems that diagnose drug-resistant infections posted revenue of $1.8 million in the period, missing Street forecasts. Three analysts surveyed by Zacks expected $2.7 million.
Accelerate Diagnostics shares have increased 45% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $16.62, a decrease of 25% in the last 12 months.